Axsome Therapeutics (AXSM) Reports Q1 Loss, Beats Revenue Estimates

Axsome Therapeutics (AXSM) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to a loss of $0.8 per share a year ago.